Peanut Allergy Patch: How Viaskin Immunotherapy Works

If your child has a peanut allergy, you have probably heard about a small adhesive patch called Viaskin Peanut that promises to retrain the immune system without a single bite of peanut. The patch delivers a tiny, measured amount of peanut protein through the skin every day, gradually raising the amount of peanut a child’s body can tolerate before reacting. It is not a cure, and it is not yet approved for use in the United States. Still, the science behind it, known as epicutaneous immunotherapy, has moved further along than almost any other peanut allergy treatment currently in development.

For families who manage peanut allergy through strict avoidance and constant label-checking, a patch that does not involve swallowing the allergen or getting an injection is worth understanding now, before it reaches pharmacy shelves. Here is what the patch actually does inside the body, what the clinical trial numbers show, and where the approval process stands.

Key Takeaways

• The Viaskin peanut patch delivers a small dose of peanut protein through the skin daily, aiming to raise the amount of peanut a child can tolerate without a severe reaction.
• In the Phase 3 VITESSE trial, 46.6% of children on the patch became treatment responders after twelve months, compared with 14.8% on placebo.
• The patch is not yet FDA-approved; DBV Technologies plans to file for approval in late 2026 for children ages four to seven.
• Unlike oral immunotherapy, the patch does not require swallowing peanut protein, which may lower the risk of severe reactions during treatment.
• Even if approved, families will still need an allergy action plan, epinephrine on hand, and ongoing avoidance strategies.

What Is The Viaskin Peanut Patch

The Viaskin peanut patch is a small, coin-sized adhesive disc worn on the skin, usually between the shoulder blades or on the upper arm. Inside the patch is a dry film of peanut protein that dissolves slightly with skin moisture, allowing a controlled amount of allergen to sit against the outer layer of skin. A child wears the patch for several hours a day, replacing it daily, without the peanut protein ever entering the mouth or digestive system.

This delivery method is called epicutaneous immunotherapy, often shortened to EPIT. It differs from oral immunotherapy, where a child eats measured amounts of peanut flour, and from injectable biologics that work through the bloodstream. Instead, the patch uses the skin to introduce the allergen to the immune system in small, steady amounts.

How Epicutaneous Immunotherapy Works Under The Skin

The outer layer of skin is packed with immune cells called Langerhans cells, which normally act as sentries against outside particles. When peanut protein from the patch settles on the skin’s surface, these cells capture it and carry it to nearby lymph nodes. Research on this pathway shows that allergen uptake by Langerhans cells triggers the production of regulatory T cells, immune cells that dampen an allergic response rather than provoke one.

Over months of daily wear, this shift can gradually retrain the immune system to view peanut protein as less of a threat. The goal is desensitization: raising the dose of peanut a child can be exposed to, whether from a trace ingredient or an accidental bite, before the body reacts with symptoms. It is not the same as building permanent tolerance, and most children need to keep wearing the patch to maintain any protective effect.

What The Clinical Trial Data Show

The most recent and largest study of the patch, called VITESSE, enrolled 654 children ages four to eleven with a confirmed peanut allergy. According to the trial report, 46.6% of children on the active patch were considered treatment responders after twelve months, meaning they could tolerate a meaningfully higher dose of peanut protein than at the start. Only 14.8% of children in the placebo group reached that same benchmark.

A few other findings from the trial stand out:

• Nearly one-quarter of children in the placebo group actually grew more sensitive to peanut over the year, compared with about 6% of children on the active patch.
• Safety results were consistent with earlier studies of the patch, with most side effects limited to skin irritation at the application site.
• The trial’s size and design led the FDA to grant the therapy breakthrough therapy designation, a status meant to speed the review of treatments that address a serious unmet need.

These numbers matter because peanut allergy is common enough to affect a meaningful share of American children. Recent pediatric data put the rate of peanut allergy in children in the United States at around 2.2% of the pediatric population, and peanut remains one of the leading causes of severe, sudden allergic reactions in kids.

How Viaskin Compares With Other Peanut Allergy Treatments

Viaskin is not the only immune-based treatment for peanut allergy, and it will not replace every other option once approved. Families weighing treatment choices generally compare three paths:

• Oral immunotherapy (OIT): involves eating small, gradually increasing amounts of peanut protein under medical supervision. It can be effective, but it carries a higher chance of allergic reactions during dosing since the allergen passes through the digestive tract.
• Omalizumab (Xolair): an injectable biologic approved in 2024 for reducing the severity of reactions to accidental exposure across several foods, including peanut. It does not desensitize a child to peanut specifically; it raises the threshold for a serious reaction to many allergens at once.
• Viaskin patch (EPIT): delivers the allergen through the skin rather than the gut or bloodstream, which may lower the risk of reactions during treatment, though it still requires daily use over a long period.

Each option asks families something different in terms of time, monitoring, and risk tolerance. A patch that can be applied and left alone for the day may appeal to parents who have found oral immunotherapy dosing schedules difficult to sustain.

Regulatory Status And Timeline For Approval

Viaskin Peanut is not currently FDA-approved. This is the third attempt by its developer, DBV Technologies, to bring the patch to market after earlier submissions in 2018 and 2020 ran into manufacturing and efficacy concerns. Following the positive VITESSE results, the company reached an agreement with the FDA on the safety data package required for review, and it now plans to submit a formal application in late 2026 for children ages four to seven.

A separate track is underway for younger children. DBV is pursuing an accelerated approval pathway for toddlers ages one to three, pending safety data from a supplemental study, with that application expected on a later timeline. Even with breakthrough therapy designation and a potential priority review, final approval and product availability are not guaranteed, and any real-world use is still at least months away.

Who Might Benefit And What Families Should Watch For

If the patch is eventually approved, it is expected to launch first for the age group studied most closely in VITESSE: children roughly four to eleven years old with a confirmed peanut allergy. Families interested in a spot in future trials or early access programs should talk with their allergist about eligibility, since enrollment criteria based on a child’s reaction threshold to peanut protein tend to be strict.

Local skin reactions such as itching, redness, or swelling at the patch site are the most commonly reported side effect. Systemic reactions are less common but still possible, which is why any immunotherapy, including a patch, is administered and monitored under medical supervision rather than started at home on a family’s own schedule.

Whether a family eventually uses the patch, the fundamentals of allergy safety do not change. Building a food allergy action plan before school starts, learning to spot anaphylaxis symptoms early, and understanding why two epinephrine auto-injectors matter remain the backbone of day-to-day safety, patch or no patch.

Safety Considerations And Long-Term Limits

It is worth being clear about what the patch does not do. It does not eliminate a peanut allergy, and most children in the studies still needed to avoid direct peanut exposure even while wearing it. Desensitization raises the amount of peanut a child can tolerate before reacting; it does not guarantee a reaction-free life, and researchers do not yet know how long any protective effect lasts if the patch is stopped.

The wider picture of food allergy also matters here. Peanut allergy is associated with a real and sometimes severe risk of accidental exposure and anaphylaxis, and many children who develop it also show signs of other allergic conditions earlier in life, a pattern sometimes described as the atopic march. Understanding early red flags for anaphylaxis can help parents recognize risk before a formal peanut allergy diagnosis. And since allergy risk does not disappear with age, older kids and young adults transitioning out of pediatric care should stay aware of why teens and young adults face heightened risk from food allergies, since less parental oversight and more social eating situations can raise the stakes.

The patch represents a genuine advance in treatment options under study. Still, it is one tool among several, not a replacement for vigilance, emergency preparedness, or a relationship with an allergist who can guide a family through what is still, for now, an investigational therapy.

References

• Antigen Uptake by Langerhans Cells Is Required for the Induction of Regulatory T Cells and the Acquisition of Tolerance During Epicutaneous Immunotherapy in OVA-Sensitized Mice, Frontiers in Immunology (NIH/PMC)
• DBV to Make New Approval Bid for Viaskin Peanut on Phase III Trial, Clinical Trials Arena
• Encouraging Trends in Peanut Allergy Prevention: Real-World Impact of Prevention Guidelines, Pediatrics, American Academy of Pediatrics
• DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin Peanut Patch, DBV Technologies
• VITESSE Study Record (NCT05741476), ClinicalTrials.gov
• The Global Burden of Illness of Peanut Allergy: A Comprehensive Literature Review, PMC